Profiles

Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Deborah Hall and Glenn Stebbins.

 
Connection Strength
 
 
 
1.817
 
  1. Bailey M, Anderson S, Stebbins G, Barnes L, Shulman LM, Tartakovsky J, Hall DA. Comparison of motor, non-motor, and quality of life phenotype in Black and White patients with Parkinson's disease. Parkinsonism Relat Disord. 2022 03; 96:18-21.
    View in: PubMed
    Score: 0.238
  2. Kapur S, Vaughan C, Hawkins J, Stebbins G, Hall D. Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease. Neurol Clin Pract. 2021 Dec; 11(6):457-461.
    View in: PubMed
    Score: 0.236
  3. Hill EJ, Goetz CG, Stebbins GT, Hagerman R, Ouyang B, Hall DA. Placebo Response in Fragile X-associated Tremor/Ataxia Syndrome. Mov Disord Clin Pract. 2020 Apr; 7(3):298-302.
    View in: PubMed
    Score: 0.209
  4. Hall DA, Stebbins GT, Jacquemont S, Berry-Kravis E, Goetz CG, Hagerman R, Zhang L, Leehey MA. Clinimetric Properties of the Fragile X-associated Tremor Ataxia Syndrome Rating Scale. Mov Disord Clin Pract. 2019 Feb; 6(2):120-124.
    View in: PubMed
    Score: 0.193
  5. Hall DA, Hermanson M, Dunn E, Stebbins G, Merkitch D, Ouyang B, Berry-Kravis E, Jhaveri M. The Corpus Callosum Splenium Sign in Fragile X-Associated Tremor Ataxia Syndrome. Mov Disord Clin Pract. 2017 May-Jun; 4(3):383-388.
    View in: PubMed
    Score: 0.166
  6. Hall DA, Stebbins GT, Litvan I, Bordelon Y, Riley DE, Leverenz J, Standaert DG. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Mov Disord Clin Pract. 2016 Jan-Feb; 3(1):65-67.
    View in: PubMed
    Score: 0.154
  7. Hall DA, Forjaz MJ, Golbe LI, Litvan I, Payan CAM, Goetz CG, Leentjens AFG, Martinez-Martin P, Traon AP, Sampaio C, Post B, Stebbins G, Weintraub D, Schrag A. Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. Mov Disord Clin Pract. 2015 Jun; 2(2):127-134.
    View in: PubMed
    Score: 0.150
  8. Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe JA, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA. Erratum: Emerging topics in FXTAS. J Neurodev Disord. 2015; 7(1):13.
    View in: PubMed
    Score: 0.149
  9. Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe J, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA. Emerging topics in FXTAS. J Neurodev Disord. 2014; 6(1):31.
    View in: PubMed
    Score: 0.142
  10. Pal G, Mangone G, Ouyang B, Ehrlich D, Saunders-Pullman R, Bressman S, Alcalay RN, Marder K, Aasly J, Mouradian MM, Anderson S, Bernard B, Stebbins G, Sani S, Afshari M, Verhagen L, de Bie RMA, Foltynie T, Hall D, Corvol JC, Goetz CG. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 Jun 10.
    View in: PubMed
    Score: 0.061
  11. Pal G, Mangone G, Hill EJ, Ouyang B, Liu Y, Lythe V, Ehrlich D, Saunders-Pullman R, Shanker V, Bressman S, Alcalay RN, Garcia P, Marder KS, Aasly J, Mouradian MM, Link S, Rosenbaum M, Anderson S, Bernard B, Wilson R, Stebbins G, Nichols WC, Welter ML, Sani S, Afshari M, Verhagen L, de Bie RMA, Foltynie T, Hall D, Corvol JC, Goetz CG. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.060
  12. Tosin MHS, Stebbins GT, Comella C, Patterson CG, Hall DA. Does MDS-UPDRS Provide Greater Sensitivity to Mild Disease than UPDRS in De Novo Parkinson's Disease? Mov Disord Clin Pract. 2021 Oct; 8(7):1092-1099.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.